Roche Holding (ROP) Resumen de Acciones

Roche Holding AG opera en el sector farmacéutico y de diagnóstico en Europa, Norteamérica, Latinoamérica, Asia, África, Australia y Nueva Zelanda. Saber más

Análisis fundamental de ROP
Puntuación del snowflake
Valoración	4/6
Crecimiento futuro	2/6
Rendimiento pasado	4/6
Salud financiera	4/6
Dividendos	5/6

Recompensas

Cotiza un 59.5% por debajo de nuestra estimación de su valor justo

Se prevé un crecimiento anual de los beneficios de 10.3%

Paga dividendo fiable de 2.71%

Análisis de riesgos

Tiene un alto nivel de endeudamiento

ROP Community Fair Values

Create Narrative

See what 36 others think this stock is worth. Follow their fair value or set your own to get alerts.

Analyst Price Targets

2.4% infravalorado

AnalystConsensusTarget

1mo ago

Late Stage Pipeline And Diagnostics Expansion Will Reshape Long Term Prospects

Large Late Stage Pipeline And US Investment Will Support Steady Healthcare Demand

15.6% infravalorado

AnalystHighTarget

4mo ago

Late Stage Pipeline And Diagnostics Expansion Will Transform Long Term Healthcare Leadership

Top Community Narratives

Roche Holding

2.3% sobrevalorado

Roche is a cash-generating, defensive large-cap pharma, with upside driven by pipeline execution.

kapirey

Published 12 May

Read Narrative

Top Community Narratives

Roche Holding

2.3% sobrevalorado

Roche is a cash-generating, defensive large-cap pharma, with upside driven by pipeline execution.

kapirey

Published 12 May

Read Narrative

Top Analyst Narratives

2.4% infravalorado

AnalystConsensusTarget

1mo ago

Late Stage Pipeline And Diagnostics Expansion Will Reshape Long Term Prospects

Large Late Stage Pipeline And US Investment Will Support Steady Healthcare Demand

15.6% infravalorado

AnalystHighTarget

4mo ago

Late Stage Pipeline And Diagnostics Expansion Will Transform Long Term Healthcare Leadership

View all narratives

Competidores de Roche Holding AG

Historial de precios y rendimiento

Resumen de las cotizaciones máximas, mínimas y variaciones del Roche Holding
Precios históricos de las acciones
Precio actual de la acción	CHF 361.40
Máximo en las últimas 52 semanas	CHF 375.80
Mínimo de 52 semanas	CHF 252.20
Beta	0.35
Cambio en 1 mes	1.77%
Variación en 3 meses	11.54%
Cambio de 1 año	38.79%
Variación en 3 años	40.10%
Variación en 5 años	5.83%
Variación desde la OPV	1,284.67%

Noticias y actualizaciones recientes

Recent updates

Actualización de narrativa • Aug 24

ROP: Partnership And Pipeline Execution Risk Will Likely Cap Future Upside

Analysts have nudged their fair value estimate for Roche Holding to CHF 267.89 from CHF 260.11, citing a mix of higher assumed revenue growth, a slightly adjusted discount rate, modestly lower profit margin expectations, and a marginally higher future P/E. Analyst Commentary Recent Street research around Roche Holding offers a mixed picture for investors, with some firms highlighting potential growth drivers while others flag valuation and execution risks.

Actualización de narrativa • Aug 10

ROP: Pipeline Partnerships And Oncology Catalysts Will Shape Measured 2027 Outlook

Analysts have lifted their fair value estimate for Roche Holding to CHF 370.31 from CHF 359.22, citing a combination of visible growth, incremental pipeline contributions including giredestrant, and recent partnership activity. They view these factors as supporting revenue growth assumptions and profit margin resilience, despite a slightly higher discount rate and a modestly lower future P/E multiple.

Artículo de análisis • Jul 31

Roche Holding (VTX:ROP) Is Posting Promising Earnings But The Good News Doesn’t Stop There

Investors signalled that they were pleased with Roche Holding AG's ( VTX:ROP ) most recent earnings report. According...

Actualización de narrativa • Jul 27

ROP: Partnership Reliance And Pipeline Skepticism Will Likely Restrain Future Upside

Analysts lifted their fair value estimate for Roche Holding, implying a new price target of about CHF 260. They incorporated updated assumptions on revenue growth, margins and P/E following a series of partnership-focused research notes around the company's Nurix collaboration and a recent HSBC rating change.

Artículo de análisis • Jul 27

Analyst Estimates: Here's What Brokers Think Of Roche Holding AG (VTX:ROP) After Its Half-Yearly Report

Investors in Roche Holding AG ( VTX:ROP ) had a good week, as its shares rose 7.1% to close at CHF355 following the...

Actualización de narrativa • Jul 10

ROP: Pipeline Partnerships And Oncology Data Will Shape Balanced Outlook

Analysts have modestly lifted their fair value estimate for Roche Holding to CHF 359.22 from CHF 352.00, citing updated assumptions around revenue growth, profit margins and future P/E, along with mixed but generally constructive readthroughs from recent pipeline and partnership research. Analyst Commentary Recent Street research around Roche Holding points to a mixed but constructive setup, with optimism around specific products and partnerships balanced by more cautious views on the risk and timing of future growth and execution.

Actualización de narrativa • Jun 26

ROP: External Oncology Collaborations Will Likely Cap Near Term Upside

Analysts have updated their fair value estimate for Roche Holding to CHF 253.81 from CHF 295.00, reflecting refreshed assumptions on revenue growth, margins, and future P/E multiples in light of recent co-development agreements with partners such as Nurix Therapeutics. Analyst Commentary Recent Street research around Roche Holding and its partners gives you a mixed picture, with enthusiasm for the co-development agreements alongside more cautious voices highlighting execution and valuation risks.

Nueva narrativa • May 12

Roche is a cash-generating, defensive large-cap pharma, with upside driven by pipeline execution.

Investment Memo – Roche Holding AG (Pharmaceutical Division / “Roche Pharma”) 1. Executive Summary Roche is a leading global pharmaceutical and diagnostics company with a strong focus on oncology, immunology, neuroscience, and rare diseases.

Nueva narrativa • Apr 19

Late Stage Pipeline And Diagnostics Expansion Will Transform Long Term Healthcare Leadership

Catalysts About Roche Holding Roche is a global healthcare company focused on pharmaceuticals and diagnostics across oncology, neurology, immunology, ophthalmology and cardiometabolic diseases. What are the underlying business or industry changes driving this perspective?

Nueva narrativa • Apr 04

Late Stage Pipeline And Diagnostics Expansion Will Reshape Long Term Prospects

Catalysts About Roche Holding Roche Holding is a global healthcare company with large pharmaceutical and diagnostics businesses focused on prescription medicines, biologics and lab testing solutions. What are the underlying business or industry changes driving this perspective?

Nueva narrativa • Mar 21

Large Late Stage Pipeline And US Investment Will Support Steady Healthcare Demand

Catalysts About Roche Holding Roche Holding is a global healthcare group focused on pharmaceuticals and diagnostics, with a large late stage pipeline and extensive manufacturing and R&D infrastructure. What are the underlying business or industry changes driving this perspective?

Rentabilidad de los accionistas

	ROP	CH Pharmaceuticals	Mercado CH
7D	2.2%	-2.9%	-2.5%
1Y	38.8%	26.8%	11.8%

Rentabilidad vs. Industria: ROP superó a la industria Swiss Pharmaceuticals, que obtuvo un rendimiento del 26.8% el año pasado.

Rentabilidad vs. Mercado: ROP superó al mercado Swiss, que obtuvo un rendimiento del 11.8% el año pasado.

Volatilidad de los precios

Is ROP's price volatile compared to industry and market?
ROP volatility
ROP Average Weekly Movement	3.6%
Pharmaceuticals Industry Average Movement	4.4%
Market Average Movement	3.9%
10% most volatile stocks in CH Market	7.5%
10% least volatile stocks in CH Market	2.0%

Precio estable de las acciones: ROP no ha tenido una volatilidad de precios significativa en los últimos 3 meses en comparación con el mercado Swiss.

Volatilidad a lo largo del tiempo: La volatilidad semanal de ROP (4%) se ha mantenido estable durante el año pasado.

Acerca de la empresa

Fundada	Empleados	CEO	Página web
1896	103,249	Thomas Schinecker	www.roche.com

Roche Holding AG opera en el sector farmacéutico y de diagnóstico en Europa, Norteamérica, Latinoamérica, Asia, África, Australia y Nueva Zelanda. La empresa ofrece soluciones farmacéuticas en las áreas terapéuticas de anemia, sangre y tumores sólidos, dermatología, hematología, enfermedades infecciosas, inflamatorias y autoinmunes, trastornos neurológicos, oftalmología, trastornos respiratorios y trasplantes. También ofrece pruebas in vitro para el diagnóstico de diversas enfermedades, como cáncer, diabetes, Covid-19, hepatitis, virus del papiloma humano y otras; instrumentos de diagnóstico; y soluciones de salud digital.

Resumen de fundamentos de Roche Holding AG

¿Cómo se comparan los beneficios e ingresos de Roche Holding con su capitalización de mercado?
Estadísticas fundamentales de ROP
Capitalización bursátil	CHF 288.70b
Beneficios(TTM)	CHF 12.34b
Ingresos (TTM)	CHF 62.96b

23.3x

Ratio precio-beneficio (PE)

4.6x

Ratio precio-ventas (PS)

¿Está ROP sobrevalorada?

Ver valor justo y análisis de valoración

Beneficios e Ingresos

Estadísticas clave de rentabilidad del último informe de resultados (TTM)
Cuenta de resultados (TTM) de ROP
Ingresos	CHF 62.96b
Coste de los ingresos	CHF 16.26b
Beneficio bruto	CHF 46.70b
Otros gastos	CHF 34.35b
Beneficios	CHF 12.34b

Últimos beneficios comunicados

Jun 30, 2026

Próxima fecha de beneficios

Oct 22, 2026

Beneficios por acción (BPA)	15.49
Margen bruto	74.17%
Margen de beneficio neto	19.60%
Ratio deuda/patrimonio	86.6%

¿Cómo se ha desempeñado ROP a largo plazo?

Ver rendimiento histórico y comparativa

Dividendos

2.7%

Rentabilidad actual por dividendo

63%

Ratio de pagos

Análisis de la empresa y estado de los datos financieros

Datos	Última actualización (huso horario UTC)
Análisis de la empresa	2026/09/14 10:46
Precio de las acciones al final del día	2026/09/14 00:00
Beneficios	2026/06/30
Ingresos anuales	2025/12/31

Fuentes de datos

Los datos utilizados en nuestro análisis de empresas proceden de S&P Global Market Intelligence LLC. Los siguientes datos se utilizan en nuestro modelo de análisis para generar este informe. Los datos están normalizados, lo que puede introducir un retraso desde que la fuente está disponible.

Paquete	Datos	Marco temporal	Ejemplo Fuente EE.UU. ^*
Finanzas de la empresa	10 años	Cuenta de resultados Estado de tesorería Balance	Formulario SEC 10-K Formulario SEC 10-Q
Estimaciones del consenso de analistas	+3 años	Previsiones financieras Objetivos de precios de los analistas	Informes de análisis Blue Matrix
Precios de mercado	30 años	Precios de las acciones Dividendos, escisiones y acciones	Datos de mercado ICE Formulario S-1 de la SEC
Propiedad	10 años	Accionistas principales Información privilegiada	Formulario SEC 4 Formulario SEC 13D
Gestión	10 años	Equipo directivo Consejo de Administración	Formulario SEC 10-K Formulario SEC DEF 14A
Principales avances	10 años	Anuncios de empresas	Formulario SEC 8-K

^* Ejemplo para valores de EE.UU., para no EE.UU. se utilizan formularios y fuentes normativas equivalentes.

A menos que se especifique lo contrario, todos los datos financieros se basan en un periodo anual, pero se actualizan trimestralmente. Esto se conoce como datos de los últimos doce meses (TTM) o de los últimos doce meses (LTM). Más información.

Modelo de análisis y copo de nieve

Los detalles del modelo de análisis utilizado para generar este informe están disponibles en nuestra página de Github, también tenemos guías sobre cómo utilizar nuestros informes y tutoriales en Youtube.

Conozca al que diseñó y construyó el modelo de análisis Simply Wall St.

Métricas industriales y sectoriales

Simply Wall St calcula cada 6 horas nuestras métricas sectoriales y de sección. Los detalles de nuestro proceso están disponibles en Github.

Fuentes analistas

Roche Holding AG está cubierta por 45 analistas. 19 de esos analistas presentaron las estimaciones de ingresos o ganancias utilizadas como datos para nuestro informe. Las estimaciones de los analistas se actualizan a lo largo del día.

Analista	Institución
John Staszak	Argus Research Company
Gerhard Schwarz	Baader Helvea Equity Research
Mark Purcell	Barclays

Roche Holding (ROP) Resumen de Acciones

Recompensas

Análisis de riesgos

Analyst Price Targets

Late Stage Pipeline And Diagnostics Expansion Will Reshape Long Term Prospects

Large Late Stage Pipeline And US Investment Will Support Steady Healthcare Demand

Late Stage Pipeline And Diagnostics Expansion Will Transform Long Term Healthcare Leadership

Top Community Narratives

Roche is a cash-generating, defensive large-cap pharma, with upside driven by pipeline execution.

Top Community Narratives

Roche is a cash-generating, defensive large-cap pharma, with upside driven by pipeline execution.

Top Analyst Narratives

Late Stage Pipeline And Diagnostics Expansion Will Reshape Long Term Prospects

Large Late Stage Pipeline And US Investment Will Support Steady Healthcare Demand

Late Stage Pipeline And Diagnostics Expansion Will Transform Long Term Healthcare Leadership

Competidores de Roche Holding AG

Novartis

Galderma Group

Sandoz Group

Dottikon ES Holding

Historial de precios y rendimiento

Noticias y actualizaciones recientes

Roche Advances Global Plans After Tam-Peli Lung Cancer Trial Shows Survival Benefit

FDA Priority Review Advances Roche Enspryng Bid for First MOGAD Therapy Approval

Roche Receives U.S. FDA Priority Review for Enspryng for MOGAD

Roche to Launch Phase 1 Combination Trial With Treeline in B-Cell Lymphomas

New minor risk - Dividend sustainability

Roche Presents Two-Year Results From The SALWEEN Study Of Vabysmo In Polypoidal Choroidal Vasculopathy

Recent updates

Roche Advances Global Plans After Tam-Peli Lung Cancer Trial Shows Survival Benefit

FDA Priority Review Advances Roche Enspryng Bid for First MOGAD Therapy Approval

Roche Receives U.S. FDA Priority Review for Enspryng for MOGAD

Roche to Launch Phase 1 Combination Trial With Treeline in B-Cell Lymphomas

New minor risk - Dividend sustainability

Roche Presents Two-Year Results From The SALWEEN Study Of Vabysmo In Polypoidal Choroidal Vasculopathy

Roche Receives FDA Approval For Companion Diagnostic Tests to Identify Patients With HER2-Positive Metastatic Gastroesophageal Adenocarcinoma Eligible For ZIIHERA

Roche Licenses Hanmi Obesity Drug Candidate in $2.3 Billion Deal With Genentech

Roche Receives FDA Clearance For Elecsys Ptau217 Blood Test For Alzheimer’s Disease Assessment

ROP: Partnership And Pipeline Execution Risk Will Likely Cap Future Upside

Genentech to Expand Hillsboro Facility With $750 Million Investment for Advanced Injectables

Genentech Reaches Construction Milestone for $2 Billion North Carolina Biomanufacturing Facility

ChemoMetec and Roche Team Up on Cedex Bio Analyzer Integration Collaboration

ROP: Pipeline Partnerships And Oncology Catalysts Will Shape Measured 2027 Outlook

Roche Holding Teams With Evexta Bio for Phase 1b Breast Cancer Drug Trial

Roche Holding (VTX:ROP) Is Posting Promising Earnings But The Good News Doesn’t Stop There

ROP: Partnership Reliance And Pipeline Skepticism Will Likely Restrain Future Upside

Analyst Estimates: Here's What Brokers Think Of Roche Holding AG (VTX:ROP) After Its Half-Yearly Report

Roche Gains FDA Clearance for cobas BV/CV Molecular Vaginitis Diagnostic

First half 2026 earnings released

CHMP Backs EU Approval for Susvimo Continuous Eye Treatment in Roche Milestone

Roche Receives Positive CHMP Recommendation For Susvimo For Neovascular Age-Related Macular Degeneration

Roche Receives FDA Clearance For The Cobas BV/CV Assay Enabling Fast And Highly Accurate Vaginitis Diagnosis

Roche Names Dan Malarek CEO of Diagnostics North America as Leadership Team Shifts

FDA Sets Priority Review for Roche’s Gazyva in Rare Kidney Disease Therapy Decision

Roche Announces FDA Grants Priority Review to Roche’s Gazyva/Gazyvaro for Adults with Primary Membranous Nephropathy

Roche Unveils First Fully Automated HDV Test for Severe Hepatitis Detection and Monitoring

Roche Introduces Cobas Hepatitis D Virus Test for Use on Cobas 5800/6800/8800 Systems

ROP: Pipeline Partnerships And Oncology Data Will Shape Balanced Outlook

Roche Receives CE Mark for Automated Tuberculosis Blood Test Across Europe

Roche Presents New Data in Alzheimer’S Disease Portfolio At Aaic 2026

Roche Reports Positive Results from Phase Iii Krascendo 1 Study Evaluating Divarasib Against Approved Kras G12c Inhibitors in Previously Treated Kras G12c Non-Small Cell Lung Cancer

FDA Accepts Priority Review for Roche Enspryng in Thyroid Eye Disease Expansion

Roche Announces FDA Acceptance and Priority Review of Supplemental Biologics License Application for Enspryng for Thyroid Eye Disease

Roche Announces Launch Of AXELIOS 1 Sequencing Platform

ROP: External Oncology Collaborations Will Likely Cap Near Term Upside

Roche Backs Orano Med to Advance Lead-212 Radiopharma Cancer Therapies

Roche Receives FDA Acceptance for Supplemental Biologics License Application For Lunsumio And Polivy Combination For Relapsed Or Refractory Large B-Cell Lymphoma

Roche Receives FDA Approval for the First Companion Diagnostic to Assess PTEN Protein in People Living with Prostate Cancer

Roche Expands Cancer Diagnostics and Awaits FDA Decision on Tecentriq for Colon Cancer

Roche Announces FDA Grants Priority Review For Roche's Tecentriq For A Certain Type Of Stage III Colon Cancer

Roche Advances Breast Cancer Pipeline With FDA Review for Giredestrant and Companion Diagnostic Approval

Roche Receives FDA Acceptance For New Drug Application For Giredestrant In ER-Positive Early-Stage Breast Cancer

Foundation Medicine Receives Fda Approval for Foundationone Cdx as Companion Diagnostic for Itovebi (Inavolisib) in Combination with Palbociclib and Fulvestrant

Roche Launches the Liver Disease Panel Suite of Certified Algorithms to Support Chronic Liver Disease Management

Roche is a cash-generating, defensive large-cap pharma, with upside driven by pipeline execution.

Roche Receives CE Mark For Elecsys Ptau217 Blood Test For Alzheimer’S Disease Pathology

Roche Holding AG (SWX:ROP) entered into a definitive merger agreement to acquire PathAI, Inc. for $1.1 billion.

Roche Showcases Ophthalmology Portfolio At Arvo 2026

Roche Announces FDA Acceptance of Application for Gazyva Gazyvaro for Treatment of Systemic Lupus Erythematosus

Late Stage Pipeline And Diagnostics Expansion Will Transform Long Term Healthcare Leadership